Suppression of Cell-Mediated Immunity by Down-regulation of Interleukin-12
Giorgio Trinchieri, Maria Wysocka, and Christopher L. Karp
Antibodies and other ligands that bind to CD46 and other complement receptors may be developed for treatment of a variety of auto-immune disorders, including arthritis, graft-versus-host disease, lupus, multiple sclerosis and Crohn's disease.
U.S. Patent No. 6,086,876.
Wistar is seeking an exclusive license for this technology.